TURNER DANIEL K III 4
4 · Orexigen Therapeutics, Inc. · Filed Dec 14, 2010
Insider Transaction Report
Form 4
TURNER DANIEL K III
Director
Transactions
- Sale
Common Stock
2010-12-13−266,365→ 598,712 total(indirect: By Montreux Equity Partners II, SBIC, LP, Montreux Equity Partners III, SBIC, LP and related funds) - Sale
Common Stock
2010-12-10−333,635→ 865,077 total(indirect: By Montreux Equity Partners II, SBIC, LP, Montreux Equity Partners III, SBIC, LP and related funds)
Footnotes (7)
- [F1]60,152 of the 333,635 share sold, were sold by Montreux Equity Partners II SBIC, L.P. 273,483 of the 333,635 shares sold, were sold by Montreux Equity Partners III SBIC, L.P.
- [F2]The sale price for 273,483 of the 333,625 shares reported in this Form 4 was between the range of $8.84 per share and $8.55 per share, with the average sale price of $8.6131. The sale price for 60,152 of the 333,625 shares reported in this Form 4 was between the range of $8.80 per share and $8.60 per share, with the average sale price of $8.6825. Full information regarding the number of shares sold at each seperate price will be provided to the Commission staff upon request.
- [F3]Of the total 865,077 total shares beneficially owned following the reported transaction, 439,204 shares are held by Montreux Equity Partners II SBIC, L.P. and 425,873 shares are held by Montreux Equity Partners III SBIC, L.P.
- [F4]The reported securities are owned directly by Montreux Equity Partners II SBIC, L.P., ("MEP II") and Montreux Equity Partners III SBIC, L.P, ("MEP III"). The voting and disposition of the shares held by MEP II and MEP III are determined by Montreux Equity Management II SBIC, LLC, ("MEM II") and Montreux Equity Management III SBIC, LLC, ("MEM III"), respectively. Mr. Turner is a managing member of MEM II and MEM III. Mr. Turner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
- [F5]239,848 of the 266,365 share sold, were sold by Montreux Equity Partners II SBIC, L.P. 26,517 of the 266,365 shares sold, were sold by Montreux Equity Partners III SBIC, L.P.
- [F6]The sale price for 26,517 of the 266,365 shares reported in this Form 4 was between the range of $8.71 per share and $8.60 per share, with an average sale price of $8.6452. The sale price for 239,848 of the 266,365 shares reported in this Form 4 was between the range of $8.68 per share and $8.60 per share, with an average sale price of $8.6094.Full information regarding the number of shares sold at each seperate price will be provided to the Commission staff upon request.
- [F7]Of the total 598,712 total shares beneficially owned following the reported transaction, 199,356 shares are held by Montreux Equity Partners II SBIC, L.P. and 399,356 shares are held by Montreux Equity Partners III SBIC, L.P.